NCT01099540已完成2 期
Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- response rate
研究概览
简要总结
To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy
排除标准
- •poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma
研究组 & 干预措施
Pazopanib
Experimental
干预措施: Pazopanib (Drug)
结局指标
主要结局
response rate
时间窗: 1~2 year
次要结局
未报告次要终点
研究者
Jeeyun Lee
Professor
Samsung Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic LiposarcomaSurgically Unresectable LiposarcomaMetastatic LiposarcomaLiposarcomaNCT01506596Vector Oncology42
已完成
2 期
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic ChondrosarcomaChondrosarcomaMetastatic ChondrosarcomaNCT01330966George Clinical Pty Ltd47
终止
2 期
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung CancerLung Cancer, Non-Small CellNCT00549328GlaxoSmithKline14
进行中（未招募）
1 期
A study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma.Surgically unresectable or metastatic chondrosarcomaEUCTR2013-004851-19-GBACORN Research, LLC47
进行中（未招募）
1 期
Pazopanib for advanced and chemorefractory germ-cell tumors.Testicular or extragonadal germ cell tumors.MedDRA version: 14.1Level: HLTClassification code 10018187Term: Genitourinary neoplasms malignancy and gender unspecifiedSystem Organ Class: 100000004864EUCTR2012-004910-33-ITISTITUTO NAZIONALE PER LA CURA TUMORI43